SCHEMBL4131927

SCHEMBL4131927

CCCOc1cc2c(OCCC)cccc2cc1/C=C1/SC(Nc2ccc(C(Br)C(=O)O)cc2)=NC1=O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 10/20 0.42
MEN1 O00255 7/20 0.42
NPC1 O15118 2/20 0.39
TDP1 Q9NUW8 3/20 0.35
POLB P06746 4/20 0.34
MAPT P10636 5/20 0.34
HPGD P15428 2/20 0.34
PABPC1 P11940 1/20 0.34
APOBEC3A P31941 1/20 0.34
APOBEC3G Q9HC16 1/20 0.34
CISD1 Q9NZ45 1/20 0.33
KDM4E B2RXH2 4/20 0.33
ALDH1A1 P00352 4/20 0.33
RECQL P46063 2/20 0.33
LMNA P02545 1/20 0.33
RAB9A P51151 1/20 0.33
NSD2 O96028 1/20 0.32
APEX1 P27695 1/20 0.32
CTDSP1 Q9GZU7 1/20 0.32
ALOX5 P09917 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4131931 1.00 KMT2A (0.42) KMT2AMEN1NPC1TDP1POLB
SCHEMBL4127484 0.89 MEN1 (0.39) KMT2AMEN1NPC1TDP1POLB
SCHEMBL4127491 0.89 MEN1 (0.39) KMT2AMEN1NPC1TDP1POLB
SCHEMBL4128846 0.87 MEN1 (0.43) KMT2AMEN1NPC1TDP1POLB
SCHEMBL4128848 0.87 MEN1 (0.43) KMT2AMEN1NPC1TDP1POLB
SCHEMBL4127232 0.83 KMT2A (0.39) KMT2AMEN1NPC1TDP1POLB
SCHEMBL4127235 0.83 KMT2A (0.39) KMT2AMEN1NPC1TDP1POLB
SCHEMBL4635223 0.82 MEN1 (0.39) KMT2AMEN1NPC1TDP1POLB
SCHEMBL4635225 0.81 KMT2A (0.40) KMT2AMEN1NPC1TDP1POLB
Acetic Acid SCHEMBL4133643 0.81 TDP1 (0.36) KMT2AMEN1NPC1TDP1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090088432-A1 Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors TORRENT PHARMACEUTICALS LIMITED (IN) 2009-04-02 US claimed
EP-1934192-A1 THIAZOLINONES AND OXAZOLINONES AND THEIR USE AS PTP1B INHIBITORS Torrent Pharmaceuticals Ltd (IN) 2008-06-25 EP claimed
WO-2007032028-A1 THIAZOLINONES AND OXAZOLINONES AND THEIR USE AS PTP1B INHIBITORS TORRENT PHARMACEUTICALS LTD. (IN) 2007-03-22 WO claimed
US-20090088432-A1 Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors TORRENT PHARMACEUTICALS LIMITED (IN) 2009-04-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090088432-A1 Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors PTPRF, PTPA, PTPRJ KMT2A 2895/4885MEN1 4075/4885NPC1 2256/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.